

# FACT SHEET FOR HEALTHCARE PROVIDERS

Cue Health Inc.  
Cue COVID-19 Test

Updated: March 1, 2022

Coronavirus  
Disease 2019  
(COVID-19)

This Fact Sheet informs you of the significant known and potential risks and benefits of the emergency use of the Cue COVID-19 Test.

The Cue COVID-19 Test is authorized for use with direct anterior nasal swabs or in previously collected anterior nasal swab specimens in viral transport media from individuals with or without symptoms or other epidemiological reasons to suspect a COVID-19.

**This test is to be performed only using direct anterior nasal swabs or in previously collected anterior nasal swab specimens in viral transport media from individuals with or without symptoms or other epidemiological reasons to suspect a COVID-19.**

**All patients whose specimens are tested with this assay will receive the Fact Sheet for Patients: Cue Health Inc.- Cue COVID-19 Test.**

## What are the symptoms of COVID-19?

Many patients with confirmed COVID-19 have developed fever and/or symptoms of acute respiratory illness (e.g., cough, dyspnea). The current information available to characterize the spectrum of clinical illness associated with COVID-19 suggests that symptoms include cough, shortness of breath or dyspnea, fever, chills, myalgias, headache, sore throat or new loss of taste or smell. Based on what is known about the virus that causes COVID-19, signs and symptoms may appear any time from 2 to 14 days after exposure to the virus, and the median incubation period is approximately 5 days. For further information on the symptoms of COVID-19 please see the link provided in "*Where can I go for updates and more information?*" section at the end of this document.

Public health officials have identified cases of COVID-19 throughout the world, including the United States. Please check the CDC COVID-19 webpage (see link provided in "*Where can I go for updates and more information?*" section) for the most up to date information.

## What do I need to know about COVID-19 testing?

Current information on COVID-19 for healthcare providers is available at CDC's webpage, *Information for Healthcare Professionals* (see links provided in "*Where can I go for updates and more information?*" section).

- The Cue COVID-19 Test can be used to test direct anterior nasal swabs or in previously collected anterior nasal swab specimens in viral transport media from individuals with or without symptoms or other epidemiological reasons to suspect a COVID-19.
- The Cue COVID-19 Test is only authorized for use in laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet the requirements to perform high, moderate or waived complexity tests.
- The Cue COVID-19 Test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.

Specimens should be collected with appropriate infection control precautions. Current guidance is available at the CDC's website (see links provided in "*Where can I go for updates and more information?*" section).

When collecting and handling specimens from individuals suspected of being infected with the virus that causes COVID-19, appropriate personal protective equipment should be used as outlined in the CDC *Interim Laboratory Biosafety Guidelines for Handling and Processing*

*Specimens Associated with Coronavirus Disease 2019 (COVID-19)*. For additional information, refer to CDC *Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons Under Investigation (PUIs) for Coronavirus Disease 2019 (COVID-19)* (see links provided in "*Where can I go for updates and more information?*" section).

**Report Adverse events**, including problems with test performance or results, to MedWatch by submitting the online FDA Form 3500 (<https://www.accessdata.fda.gov/scripts/medwatch/index.cfm?action=reporting.home>) or by calling **1-800-FDA-1088**

# FACT SHEET FOR HEALTHCARE PROVIDERS

Cue Health Inc.  
Cue COVID-19 Test

Updated: March 1, 2022

Coronavirus  
Disease 2019  
(COVID-19)

## What does it mean if the specimen tests positive for the virus that causes COVID-19?

A positive test result for COVID-19 indicates that RNA from SARS-CoV-2 was detected, and therefore the patient is infected with the virus and presumed to be contagious.

Test results should always be considered in the context of clinical observations and epidemiological data in making a final diagnosis and patient management decisions. Patient management should be made by a healthcare provider and follow current CDC guidelines.

The Cue COVID-19 Test has been designed to minimize the likelihood of false positive test results. However, in the event of a false positive result, risks to patients could include the following: a recommendation for isolation of the patient, monitoring of household or other close contacts for symptoms, patient isolation that might limit contact with family or friends and may increase contact with other individuals with COVID-19, limits in the ability to work, the delayed diagnosis and treatment for the true infection causing the symptoms, unnecessary prescription of a treatment or therapy, or other unintended adverse effects.

The Cue Health Mobile Application (Cue Health App) automatically reports test results according to the reporting guidelines of the appropriate public health authorities.

## What does it mean if the specimen tests negative for the virus that causes COVID-19?

A negative test result for this test means that SARS-CoV-2 RNA was not present in the specimen above the limit of detection. However, a negative result does not rule out COVID-19 and should not be used as the sole basis for treatment or patient management decisions. It is possible to test a person too early or too late during SARS-CoV-2 infection to make an accurate diagnosis via Cue COVID-19 Test.

In addition, asymptomatic people infected with COVID-19 may not shed enough virus to reach the limit of detection of the test, giving a false negative result. In the absence of symptoms, it is difficult to determine if

asymptomatic people have been tested too late or too early. Therefore, negative results in asymptomatic individuals may include individuals who were tested too early and may become positive later, individuals who were tested too late and may have serological evidence of infection, or individuals who were never infected.

When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. The possibility of a false negative result should especially be considered if the patient's recent exposures or clinical presentation indicate that COVID-19 is likely, and diagnostic tests for other causes of illness (e.g., other respiratory illness) are negative. If COVID-19 is still suspected based on exposure history together with other clinical findings, re-testing with an alternative method should be considered by healthcare providers in consultation with public health authorities. Additional testing may be helpful to ensure testing was not conducted too early.

Risks to a patient of a false negative test result include: delayed or lack of supportive treatment, lack of monitoring of infected individuals and their household or other close contacts for symptoms resulting in increased risk of spread of COVID-19 within the community, or other unintended adverse events.

The performance of this test was established based on the evaluation of a limited number of clinical specimens. The clinical performance has not been established in all circulating variants but is anticipated to be reflective of the prevalent variants in circulation at the time and location of the clinical evaluation. Performance at the time of testing may vary depending on the variants circulating, including newly emerging strains of SARS-CoV-2 and their prevalence, which change over time.

## What is an EUA?

The United States FDA has made this test available under an emergency access mechanism called an Emergency Use Authorization (EUA). The EUA is supported by the Secretary of Health and Human Service's (HHS's) declaration that circumstances exist to justify the emergency use of in vitro diagnostics (IVDs)

**Report Adverse events**, including problems with test performance or results, to MedWatch by submitting the online FDA Form 3500 (<https://www.accessdata.fda.gov/scripts/medwatch/index.cfm?action=reporting.home>) or by calling **1-800-FDA-1088**

# FACT SHEET FOR HEALTHCARE PROVIDERS

Cue Health Inc.  
Cue COVID-19 Test

Updated: March 1, 2022

Coronavirus  
Disease 2019  
(COVID-19)

for the detection and/or diagnosis of the virus that causes COVID-19.

An IVD made available under an EUA has not undergone the same type of review as an FDA-approved or cleared IVD. FDA may issue an EUA when certain criteria are met, which includes that there are no adequate, approved, available alternatives, and based on the totality of scientific evidence available, it is reasonable to believe that this IVD may be effective in diagnosing COVID-19.

The EUA for this test is in effect for the duration of the COVID-19 declaration justifying emergency use of IVDs, unless terminated or revoked (after which the test may no longer be used).

## What are the approved available alternatives?

Any tests that have received full marketing status (e.g., cleared, approved), as opposed to an EUA, by FDA can be found by searching the medical device databases here: <https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/medical-device-databases>. A cleared or approved test should be used instead of a test made available under an EUA, when appropriate and available. FDA has issued EUAs for other tests that can be found at: <https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization>.

## Where can I go for updates and more information?

### **CDC webpages:**

**General:** <https://www.cdc.gov/coronavirus/2019-ncov/index.html>

### **Symptoms:**

<https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html>

### **Healthcare Professionals:**

<https://www.cdc.gov/coronavirus/2019-nCoV/hcp/index.html>

### **Information for Laboratories:**

<https://www.cdc.gov/coronavirus/2019-nCoV/lab/index.html>

**Laboratory Biosafety:** <https://www.cdc.gov/coronavirus/2019-nCoV/lab-biosafety-guidelines.html>

### **Isolation Precautions in Healthcare Settings:**

<https://www.cdc.gov/infectioncontrol/guidelines/isolation/index.html>

**Specimen Collection:** <https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical-specimens.html>

**Infection Control:** <https://www.cdc.gov/coronavirus/2019-ncov/php/infection-control.html>

### **FDA webpages:**

**General:** [www.fda.gov/novelcoronavirus](http://www.fda.gov/novelcoronavirus)

**EUAs:**(includes links to patient fact sheet and manufacturer's instructions) <https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas>

### **Cue Health Inc\*:**

4980 Carroll Canyon Rd. Suite 100  
San Diego, CA 92121, USA

**Email:** [support@cuehealth.com](mailto:support@cuehealth.com)

**Phone:** 833.CUE.TEST (833.283.8378)

**Website:** [www.cuehealth.com](http://www.cuehealth.com)

*\*Cue and the Cue logo are registered trademarks of Cue Health Inc.*

**Report Adverse events**, including problems with test performance or results, to MedWatch by submitting the online FDA Form 3500 (<https://www.accessdata.fda.gov/scripts/medwatch/index.cfm?action=reporting.home>) or by calling **1-800-FDA-1088**